Trabectedin in patients with pre-treated advanced soft tissue sarcoma: a retrospective single center analysis

Koseła, Hanna; Wiater, Katarzyna; Świtaj, Tomasz; Klimczak, Anna; Kamycka, Agnieszka; Falkowski, Sławomir; Ługowska, Iwona; Rutkowski, Piotr

doi:10.5114/wo.2011.26437

Cited by 1 publication

(2 citation statements)

References 22 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The third unbound C ring affects critical nuclear proteins, mainly transcription factors. Trabectedin induces DNA alkylation and DNA-protein crosslinks which cause formation of DNA strand breaks [ 7 , 9 , 10 ]. The mechanism of action is based on inhibition of DNA transcription.…”

Section: Trabectedin – Structure and Mechanism Of Actionmentioning

confidence: 99%

“…Trabectedin was approved in the European Union in July 2007 for the treatment of soft-tissue sarcomas (STS) in adults after failure of conventional therapy including anthracyclines and ifosfamide [ 7 , 9 , 11 ]. In a preclinical study, it demonstrated antineoplastic activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer [ 11 ].…”

Section: Trabectedin As a Single Agentmentioning

confidence: 99%

See 1 more Smart Citation

Review Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells

Marczak¹

2014

View full text Add to dashboard Cite

Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas. This drug shows a mechanism of action based on the inhibition of the nucleotide excision repair system. Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines. Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity.

show abstract

Section: Trabectedin – Structure and Mechanism Of Actionmentioning

confidence: 99%